Prevalence of antibiotic resistance in anaerobic bacteria: Worrisome developments

Clinical Infectious Diseases

Volumn 39, Issue 1, 2004, Pages 92-97

  Hecht, David W ^a,b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; METRONIDAZOLE; QUINOLONE;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; DRUG SENSITIVITY; EMPIRICISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; DRUG RESISTANCE; DRUG RESISTANCE, BACTERIAL; GENE FREQUENCY; HUMANS; MICROBIAL SENSITIVITY TESTS; TRANSDUCTION, GENETIC;

EID: 3042835898     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421558     Document Type: Review

References (47)

1. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000; 30:870-6.
2. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 6th ed. Villanova, PA: NCCLS, 2004. Document no. M11-A6.
3. Citron DM, Hecht DW. Susceptibility test methods: anaerobic bacteria. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: American Society for Microbiology Press, 2003:1141-8.
4. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 4th ed. Villanova, PA: NCCLS, 1997. Document no. M11-A4.
5. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis 2002; 35:5126-34.
6. Cornick NA, Cuchural GJ Jr, Snydman DR, et al. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother 1990; 25:1011-9.
7. Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999; 43:2417-22.
8. Hecht DW, Osmolski JR, O'Keefe JP. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis 1993; 16(Suppl 4):S357-60.
9. Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001; 45:1238-43.
10. Drummond LJ, McCoubrey J, Smith DG, Starr JM, Poxton IR. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 2003; 52:259-63.
11. Hecht DW, Vedantam G. Anaerobe resistance among anaerobes: what now? Anaerobe 1999; 5:421-9.
12. Jimenez-Diaz A, Reig M, Baquero F, Ballesta JP. Antibiotic sensitivity of ribosomes from wild-type and clindamycin resistant Bacteroides vulgatus strains. J Antimicrob Chemother 1992; 30:295-301.
13. Rasmussen BA, Bush K, Tally FP, Antimicrobial resistance in anaerobes. Clin Infect Dis 1997; 24(Suppl 1):S110-20.
14. Privitera G, Dublanchet A, Sebald M. Transfer of multiple antibiotic resistance between subspecies of Bacteroides fragilis. J Infect Dis 1979; 139:97-101.
15. Welch RA, Jones KR, Macrina FL. Transferable lincosamide-macrolide resistance in Bacteroides. Plasmid 1979; 2:261-8.
16. Tally FP, Snydman DR, Gorbach SL, Malamy MH. Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. J Infect Dis 1979; 139:83-8.
17. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997-1005.
18. Goldstein EJ, Citron DM, Vreni MC, Warren Y, Tyrrell KL. Comparative in vitro activities of ertapenem (MK-0826) against 1001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2000; 44:2389-94.
19. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9:475-88.
20. Appelbaum PC, Philippon A, Jacobs MR, Spangler SK, Gutmann L. Characterization of β-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in β-lactam resistance. Antimicrob Agents Chemother 1990; 34:2169-76.
21. Giraud-Morin C, Madinier I, Fosse T. Sequence analysis of cfxA2-like β-lactamases in Prevotella species. J Antimicrob Chemother 2003; 51:1293-6.
22. Rogers MB, Parker AC, Smith CJ. Cloning and characterization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of Ambler class A β-lactamases. Antimicrob Agents Chemother 1993; 37:2391-400.
23. Appelbaum PC, Spangler SK, Pankuch, GA et al. Characterization of a β-lactamase from Clostridium clostridioforme. J Antimicrob Chemother 1994; 33:33-40.
24. Yang Y, Rasmussen BA, Bush K. Biochemical characterization of the metallo-β-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother 1992; 36:1155-7.
25. Cuchural GJ Jr, Malamy MH, Tally FP. β-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother 1986; 30:645-8.
26. Podglajen I, Breuil J, Casin I, Collatz E. Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content. J Bacteriol 1995; 177:5270-5.
27. Podglajen I, Breuil J, Bordon F, Gutmann L, Collatz E. A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiol Lett 1992; 70:21-9.
28. Podglajen I, Breuil J, Collatz E. Insertion of a novel DNA sequence, 1S1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol Microbiol 1994; 12:105-14.
29. Edwards R, Read PN. Expression of the carbapenemase gene (cfiA) in Bacteroides fragilis. J Antimicrob Chemother 2000; 46:1009-12.
30. Wexler HM, Halebian S. Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-β-lactamase mediated cefoxitin resistance. J Antimicrob Chemother 1990; 26:7-20.
31. Fang H, Edlund C, Nord CE, Hedberg M. Selection of cefoxitin-resistant Bacteroides thetaiotaomicron mutants and mechanisms involved in β-lactam resistance. Clin Infect Dis 2002; 35:S47-53.
32. Wexler HM. Outer-membrane pore-forming proteins in gram-negative anaerobic bacteria. Clin Infect Dis 2002; 35:S65-71.
33. Breuil J, Dublanchet A, Truffaut N, Sebald M. Transferable 5-nitroimidazole resistance in the Bacteroides fragilis group. Plasmid 1989; 21:151-4.
34. Urban E, Soki J, Brazier JS, Nagy E, Duerden BI. Prevalence and characterization of nim genes of Bacteroides sp. isolated in Hungary. Anaerobe 2002; 8:175-79.
35. Haggoud A, Reysset G, Azeddoug H, Sebald M. Nucleotide sequence analysis of two 5-nitroimidazole resistance determinants from Bacteroides strains and of a new insertion sequence upstream of the two genes. Antimicrob Agents Chemother 1994; 38:1047-51.
36. Carlier JP, Sellier N, Rager MN, Reysset G. Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis. Antimicrob Agents Chemother 1997; 41:1495-9.
37. Trinh S, Haggoud A, Reysset G, Sebald M. Plasmids pIP419 and pIP421 from Bacteroides: 5-nitroimidazole resistance genes and their upstream insertion sequence elements. Microbiology 1995; 141:927-35.
38. Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemother 1999; 44:580-1.
39. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003; 52:208-13.
40. Onodera Y, Sato K. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrob Agents Chemother 1999; 43:2423-9.
41. Bachoual R, Dubreuil L, Soussy CJ, Tankovic J. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob Agents Chemother 2000; 44:1842-5.
42. Oh H, El Amin N, Davies T, Appelbaum PC, Edlund C. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob Agents Chemother 2001; 45:1977-81.
43. Oh H, Hedberg M, Edlund C. Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group. Anaerobe 2002; 8:277-82.
44. Ricci V, Piddock L. Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J Antimicrob Chemother 2003; 52:605-9.
45. Whittle G, Shoemaker NB, Salyers AA. The role of Bacteroides conjugative transposons in the dissemination of antibiotic resistance genes. Cell Mol Life Sci 2002; 59:2044-54.
46. Bonheyo GT, Hund BD, Shoemaker NB, Salyers AA. Transfer region of a Bacteroides conjugative transposon contains regulatory as well as structural genes. Plasmid 2001; 46:202-9.
47. Shoemaker NB, Vlamakis H, Hayes K, Salyers AA. Evidence for extensive resistance gene transfer among Bacteroides spp. and among Bacteroides and other genera in the human colon. Appl Environ Microbiol 2001; 67:561-8.